search
Back to results

Hepatitis B Vaccine in Seniors

Primary Purpose

Hepatitis B Vaccination

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Subcutaneous fat injection of Recombivax-HB
Intramuscular injection of Recombivax-HB
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hepatitis B Vaccination

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy, community-dwelling adult men or women 65 years of age or older, of any race or ethnic group
  • Medical history with stable chronic non-immunologically mediated medical conditions (e.g. osteoarthritis, hypertension)
  • Normal (within the normal range for reference laboratory or clinically insignificant values as determined by the Principal Investigator) TSH, serum vitamin B12, AST/SGOT, ALT/SGPT
  • Negative serum tests for hepatitis B surface antigen and antibody, hepatitis B core antibody and hepatitis C antibody
  • Has given informed consent
  • Ready access to a telephone

Exclusion Criteria:

  • Clinically apparent or history of immunologically mediated diseases (e.g. rheumatoid arthritis, lupus erythematosis, etc.), immunodeficiency, severe cardiovascular disease, severe respiratory disease (requiring supplemental oxygen), endocrine disorder (e.g. thyroid dysfunction, adrenal insufficiency), liver disease (cirrhosis), renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder (eligible if treated and in remission), drug or alcohol abuse or currently smoking 10 cigarettes per day
  • Infections within 2 weeks of immunization (the most frequent infections are respiratory and urogenital)
  • Inflammatory processes such as known chronic infections, inflammatory bowel disease or Westergren sedimentation rate (greater than 50mm/hour for men, greater than 60mm/hour for women)
  • All malignancies (excluding non-melanotic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years
  • Arteriosclerotic event during the 2 weeks prior to enrollment (e.g. medically documented myocardial infarction, stroke, recanalization of the femoral arteries, claudication, or Transient Ischemic Attack (TIA))
  • Cardiac insufficiency, if heart failure present (New York Heart Association functional class III or IV)
  • Poorly controlled hypertension (Systolic Blood Pressure 180mmHg, Diastolic Blood Pressure 100mmHg on two separate determinations at least 10 minutes apart)
  • Renal Insufficiency (serum creatinine 2.0 or BUN 40) and stable over past 6 months
  • Elevated or low glucose (fasting 140 or less than 70, non-fasting 200)
  • Cognitive impairment: score of less than 23 on the Folstein Mini-Mental State Examination
  • Depression or mood alteration: score of 6 on the Geriatric Depression Scale
  • Malnutrition as defined by clinical judgment and by decreased serum albumin (less than 3.2g/L) or hypocholesterolemia (less than 160mg/dL), or low total lymphocyte count (less than 1500/ml3)
  • Anemia (Hct less than 30% or low serum vitamin B12 or vitamin E level)
  • History of or current alcoholism or consuming greater than 2oz of ETOH/day; current drug abuse; currently smoking 10 cigarettes per day
  • Risk factors for hepatitis B (which would indicate the need for immediate immunization with licensed vaccine), such as parenteral drug abuse, multiple sexual partners, commercial sex worker, health care worker
  • History of hepatitis B infection or vaccination
  • Positive test for hepatitis B surface antigen or antibody, hepatitis B core antibody, or hepatitis C antibody
  • History of significant bilateral upper arm injury or surgery, of any duration, because theoretically this may impede lymph drainage to regional lymph nodes
  • Reported allergy to thimerosal (i.e., contact lens solution) or yeast products
  • Unable to attend the Baltimore VA Medical Center or the Waxter Center on a regular basis; no telephone in primary residence
  • Subcutaneous fat pad less than 6 mm in thickness as determined by computer tomography
  • Medication exclusions include prednisone greater than 5 mg/day (or equal), colchicines, imuran, methotrexate, azathioprine, cyclophosphamide, cyclosporine, or interferons

Sites / Locations

  • University of Maryland, Baltimore, Center for Vaccine Development and Global Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Subcutaneous Fat Vaccine Injection

Intramuscular Vaccine Injection

Arm Description

Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.

Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.

Outcomes

Primary Outcome Measures

Hepatitis B surface antibody (HBsAb) titers (in international units/L)
Basic science - Primary and booster hepatitis B surface antibody titers to three injections of Recombivax-HB in the elderly and young adults immunized subcutaneously or intramuscularly, including % responders
Cell-mediated immune responses (CMI) (levels of interferon gamma and other cytokines in pg/ml)
Basic science - Primary and booster CMI responses to three injections of Recombivax-HB in the elderly and young adults immunized subcutaneously or intramuscularly, including % responders

Secondary Outcome Measures

Full Information

First Posted
October 31, 2019
Last Updated
November 12, 2019
Sponsor
University of Maryland, Baltimore
search

1. Study Identification

Unique Protocol Identification Number
NCT04162223
Brief Title
Hepatitis B Vaccine in Seniors
Official Title
Mechanisms of Immunosenescence: A Single-Blinded Comparison of the Location of Vaccine Inoculum, Intramuscular Versus Subcutaneous Adipose Tissue, on the Immune Response of Healthy Elderly Adults to a Recombinant Hepatitis B Surface Antigen Vaccine (Recombivax-HB)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
March 29, 2000 (Actual)
Primary Completion Date
May 20, 2003 (Actual)
Study Completion Date
May 20, 2003 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The first purpose of this study is to test the body's protective reaction (making antibodies) to a licensed hepatitis B vaccine (Recombivax-HB) after it is injected either in the arm fat or muscle. Hepatitis B virus is an important cause of liver disease in humans. More than 21% of healthy adults over age 60 years demonstrate evidence of previous Hepatitis B infection using a common blood test. The second purpose of this study is to learn more information about other reasons (such as body fat content, gene types, etc.), why older people respond less well than younger people to vaccines. The Investigators will also learn more about the ability of certain white blood cells, called T cells, to respond to protein signals in the blood. T cells do not seem to respond as well to these protein signals as individuals age. The Investigators will compare results to a younger group of volunteers who have also been vaccinated with hepatitis B vaccine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis B Vaccination

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subcutaneous Fat Vaccine Injection
Arm Type
Experimental
Arm Description
Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.
Arm Title
Intramuscular Vaccine Injection
Arm Type
Experimental
Arm Description
Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.
Intervention Type
Biological
Intervention Name(s)
Subcutaneous fat injection of Recombivax-HB
Intervention Description
Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
Intervention Type
Biological
Intervention Name(s)
Intramuscular injection of Recombivax-HB
Intervention Description
Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
Primary Outcome Measure Information:
Title
Hepatitis B surface antibody (HBsAb) titers (in international units/L)
Description
Basic science - Primary and booster hepatitis B surface antibody titers to three injections of Recombivax-HB in the elderly and young adults immunized subcutaneously or intramuscularly, including % responders
Time Frame
two years
Title
Cell-mediated immune responses (CMI) (levels of interferon gamma and other cytokines in pg/ml)
Description
Basic science - Primary and booster CMI responses to three injections of Recombivax-HB in the elderly and young adults immunized subcutaneously or intramuscularly, including % responders
Time Frame
two years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, community-dwelling adult men or women 65 years of age or older, of any race or ethnic group Medical history with stable chronic non-immunologically mediated medical conditions (e.g. osteoarthritis, hypertension) Normal (within the normal range for reference laboratory or clinically insignificant values as determined by the Principal Investigator) TSH, serum vitamin B12, AST/SGOT, ALT/SGPT Negative serum tests for hepatitis B surface antigen and antibody, hepatitis B core antibody and hepatitis C antibody Has given informed consent Ready access to a telephone Exclusion Criteria: Clinically apparent or history of immunologically mediated diseases (e.g. rheumatoid arthritis, lupus erythematosis, etc.), immunodeficiency, severe cardiovascular disease, severe respiratory disease (requiring supplemental oxygen), endocrine disorder (e.g. thyroid dysfunction, adrenal insufficiency), liver disease (cirrhosis), renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder (eligible if treated and in remission), drug or alcohol abuse or currently smoking 10 cigarettes per day Infections within 2 weeks of immunization (the most frequent infections are respiratory and urogenital) Inflammatory processes such as known chronic infections, inflammatory bowel disease or Westergren sedimentation rate (greater than 50mm/hour for men, greater than 60mm/hour for women) All malignancies (excluding non-melanotic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years Arteriosclerotic event during the 2 weeks prior to enrollment (e.g. medically documented myocardial infarction, stroke, recanalization of the femoral arteries, claudication, or Transient Ischemic Attack (TIA)) Cardiac insufficiency, if heart failure present (New York Heart Association functional class III or IV) Poorly controlled hypertension (Systolic Blood Pressure 180mmHg, Diastolic Blood Pressure 100mmHg on two separate determinations at least 10 minutes apart) Renal Insufficiency (serum creatinine 2.0 or BUN 40) and stable over past 6 months Elevated or low glucose (fasting 140 or less than 70, non-fasting 200) Cognitive impairment: score of less than 23 on the Folstein Mini-Mental State Examination Depression or mood alteration: score of 6 on the Geriatric Depression Scale Malnutrition as defined by clinical judgment and by decreased serum albumin (less than 3.2g/L) or hypocholesterolemia (less than 160mg/dL), or low total lymphocyte count (less than 1500/ml3) Anemia (Hct less than 30% or low serum vitamin B12 or vitamin E level) History of or current alcoholism or consuming greater than 2oz of ETOH/day; current drug abuse; currently smoking 10 cigarettes per day Risk factors for hepatitis B (which would indicate the need for immediate immunization with licensed vaccine), such as parenteral drug abuse, multiple sexual partners, commercial sex worker, health care worker History of hepatitis B infection or vaccination Positive test for hepatitis B surface antigen or antibody, hepatitis B core antibody, or hepatitis C antibody History of significant bilateral upper arm injury or surgery, of any duration, because theoretically this may impede lymph drainage to regional lymph nodes Reported allergy to thimerosal (i.e., contact lens solution) or yeast products Unable to attend the Baltimore VA Medical Center or the Waxter Center on a regular basis; no telephone in primary residence Subcutaneous fat pad less than 6 mm in thickness as determined by computer tomography Medication exclusions include prednisone greater than 5 mg/day (or equal), colchicines, imuran, methotrexate, azathioprine, cyclophosphamide, cyclosporine, or interferons
Facility Information:
Facility Name
University of Maryland, Baltimore, Center for Vaccine Development and Global Health
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
32355503
Citation
Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing. 2020 Apr 28;17:9. doi: 10.1186/s12979-020-00179-9. eCollection 2020.
Results Reference
derived

Learn more about this trial

Hepatitis B Vaccine in Seniors

We'll reach out to this number within 24 hrs